多吉美聯合介入治疗原发性肝癌的疗效分析.docVIP

多吉美联合介入治疗原发性肝癌的疗效分析 （附20例病例报告） 作者：李枫，王峰，李军，杨新顺 单位：大连医科大学附属第一医院介入治疗科 辽宁大连 116001 第一作者：李枫，男，1973-05-16生，辽宁大连人，汉族，2003年获中国医科大学影像医学与核医学专业硕士学位，主治医师，主要从事肿瘤的介入治疗 E-mail:lifeng120@263.net T 通讯作者：王峰 大连医科大学附属第一医院介入治疗科 辽宁大连 116001 多吉美联合介入治疗原发性肝癌的疗效分析 （附20例病例报告） 李枫，王峰，李军，杨新顺 Efficacy analysis of Nexavar combined interventional therapy for hepatocellular carcinoma (study of 20 cases) Feng Li, Feng Wang, Jun Li, Xin-Shun Yang Feng Li, Feng Wang, Jun Li, Xin-Shun Yang, Department of Interventional therapy, The First Affiliated Hospital of Dalian Medical University, Dalian 116001, China Correspondence to: Feng Wang, Department of Interventional therapy, The First Affiliated Hospital of Dalian Medical University, Dalian 116001, China. Abstract AIM: To study the efficacy comparison between Nexavar monotherapy and combined interventional therapy for treatment of hepatocellular carcinoma. METHODS: Retrospective analysis of 20 cases who systemly taking Nexavar for hepatocellular carcinoma, including 7 cases of Nexavar monotherapy, 13 cases combined interventional therapy. All patients was followed up by hospital or out-patient for 7-28 months. Primary study endpoint was tumor response rate and time to tumor progression(TTP). RESULTS: In 20 cases, 4 were achieved complete response (CR), 10 were partial response (PR), 4 with stable disease (SD) and 2 with progressed disease (PD). In Nexavar monotherapy group, CR was 0, PR was 3, SD was 2 and PD was 2. The median time to tumor progression was 16 weeks and 48 weeks respectively for Monotherapy group and combined treatment group. CONCLUSION: Nexavar combined interventional therapy for hepatocellular carcinoma can increase the tumor response rate, extend the time to tumor progression. Key words: Nexavar；interventional therapy；hepatocellular carcinoma；efficacy 摘要 目的：研究多吉美单药治疗肝癌与联合介入治疗的疗效对比。 方法：回顾性分析20例系统服用多吉美的肝癌患者，其中单药治疗的7例，联合介入治疗的13例，随访方式采用门诊随访及住院随访，随访时间7-28月。主要研究终点为肿瘤反应率和肿瘤进展时间。 结果：20例患者中，CR 4例，PR 1